Baker McKenzie client Baxter International announced that they have signed a definitive agreement under which Carlyle is to acquire Baxter's Kidney Care segment, to be named Vantive, for USD 3.8 billion. The deal represents a key milestone in Baxter’s ongoing business transformation, enabling heightened strategic clarity, operational efficiency and innovation.
The Baker McKenzie team advising Baxter includes partners Olivia Tyrrell (M&A), Christina Bullock (M&A), Christopher Guldberg (benefits), Elizabeth Ebersole (employment), Adam Aft (intellectual property), Sarah Winston (real estate) and Graham Stuart (healthcare regulatory).
The transaction is expected to close in late 2024 or early 2025, subject to receipt of customary regulatory approvals and satisfaction of other closing conditions. Learn more about the deal in Baxter's and Carlyle's press release.
With more than 2,700 deal practitioners in 45 jurisdictions, Baker McKenzie is a transactional powerhouse. The Firm's Healthcare & Life Sciences group is one of the largest of any international law firm comprising more than 800 lawyers. Baker McKenzie excels in complex, cross-border transactions; over 65% of our deals are multi-jurisdictional. The Firm has been consistently recognized as a top-three firm for cross-border M&A by volume over the past decade. The teams are a hybrid of ‘local’ and ‘global’, combining money-market sophistication with local excellence.